Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity
DV is a promising NFAT inhibitor that can protect against TNFi immunogenicity without inhibiting calcineurin phosphatase activity. Our results suggest that the future development of DV analogs may be of interest as agents to attenuate unwanted immune responses.
Authors
- He Lyu (ORCID: https://orcid.org/0000-0002-6668-9790)
- Katherine M. Eichinger (ORCID: https://orcid.org/0000-0002-0968-8513)
- Andrew T. McNutt (ORCID: https://orcid.org/0000-0001-6497-6019)
- David Ryan Koes (ORCID: https://orcid.org/0000-0002-6892-6614)
- Keito Hoshitsuki (ORCID: https://orcid.org/0000-0002-6723-0711)
- Christian A. Fernandez (ORCID: https://orcid.org/0000-0002-8535-5622)
- Aboli Bhingarkar
- Larry W. Moreland (ORCID: https://orcid.org/0000-0003-4483-0359)
- Lee McDermott
- Sanjay Rathod (ORCID: https://orcid.org/0000-0003-1755-8222)
- Yuyin Wang (ORCID: https://orcid.org/0000-0002-8641-9165)
- Yin Zhu (ORCID: https://orcid.org/0000-0001-9657-484X)
Institutions
- University of Pittsburgh (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-01-09
- DOI
- https://doi.org/10.3389/fphar.2024.1397995
- Primary Topic
- Signaling Pathways in Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Pittsburgh
- National Institutes of Health
- University of Pittsburgh School of Pharmacy